Milestone Pharmaceuticals Inc.
MIST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001408443
No open-market purchases or sales by Milestone Pharmaceuticals Inc. insiders were filed in the last 90 days; 73 institutions reported holding it in 13F filings for Q3 2026, worth $43.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $46.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, 0 vs. previous quarter
- 73
- 13F valueReported value at the end of Q3 2026
- $43.6M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$63.1M
- No comparable prior period
- Free cash flow, FY2025
- -$49.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $2.96M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 19.9M
- Shares sold short
- Change
- +185.4K
- +0.9% vs. previous
- Days to cover
- 24.83
- At average daily volume
Superinvestors holding MIST, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding MIST at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Milestone Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 (view filing) | Apr 16 | 4 days | Oliveto JosephPresident and CEO | SSale | −36.5K | $2.26 | −$82.5K | −7.6%446.2K after | 10b5-1 |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Nelson Jeffrey EdwardChief Operating Officer | SSale | −70.3K | $2.25 | −$158.2K | −58.5%49.8K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Bharucha DavidChief Medical Officer | SSale | −70.3K | $2.25 | −$158.2K | −38.3%113.2K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Hasija AmitCFO & EVP of Corp. Development | SSale | −70.3K | $2.25 | −$158.2K | −41.3%99.8K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Muller LorenzChief Commercial Officer | SSale | −64.7K | $2.25 | −$145.9K | −24.0%205.4K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Oliveto JosephPresident and CEO | SSale | −167.6K | $2.24 | −$375.3K | −25.8%482.7K after | 2 lots |
| Jan 9, 2026 (view filing) | Jan 7-8 | 2 days | Oliveto JosephPresident and CEO | SSale | −43.5K | $2.25 | −$97.9K | −12.5%303.7K after | 2 lots10b5-1 |
| Dec 5, 2022 (view filing) | Dec 1-5 | 4 days | Bharucha DavidChief Medical Officer | PPurchase | +10.0K | $4.74 | +$47.4K | New position10.0K after | 2 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Wills Robert JamesDirector | PPurchase | +15.0K | $4.93 | +$74.0K | New position15.0K after | |
| Oct 21, 2022 (view filing) | Oct 20 | 1 day | Pasternak Richard CDirector | PPurchase | +10.0K | $5.20 | +$52.0K | New position10.0K after |
Top 10 13F holders, Q3 2026
See all 73 holdersThe largest institutional positions in Milestone Pharmaceuticals Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Propel Bio Management, LLC | 9,449,727 | $8.18M | 4.34% | +2,020,137+27.2% | Added |
| Pavaki Capital Management LLC | 9,337,848 | $8.08M | 4.04% | +270,000+3.0% | Added |
| RTW Investments, LP | 7,833,336 | $6.78M | 0.07% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 5,467,247 | $4.73M | 0.01% | +56,109+1.0% | Added |
| Simplify Asset Management Inc. | 3,349,379 | $2.90M | 0.05% | 00.0% | Unchanged |
| Millennium Management LLC | 2,235,274 | $1.94M | 0.00% | −906,945−28.9% | Reduced |
| Two Sigma Investments, LP | 1,721,021 | $1.49M | 0.00% | −318,994−15.6% | Reduced |
| Kalehua Capital Management LLC | 1,651,258 | $1.43M | 1.08% | +382,021+30.1% | Added |
| RVW Wealth, LLC | 1,148,260 | $994.0K | 0.06% | +1,148,260 | New |
| Marshall Wace, LLP | 1,117,642 | $972.4K | 0.00% | −680,053−37.8% | Reduced |
Holders of 5% or more of MIST
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Milestone Pharmaceuticals Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Propel Bio Management, LLC | 13G/A | 10.10%12.6M shares | +0.20 ppfrom 9.90% | Dec 23, 20252 filings | Nov 20, 2026 | SEC |
| RTW Investments, LP | 13G/A | 9.90%12.4M shares | 0.00 ppfrom 9.90% | Feb 12, 20216 filings | May 15, 2026 | SEC |
| Pavaki Capital Management LLC | 13G | 7.30%9.07M shares | New | Aug 7, 20261 filing | Aug 7, 2026 | SEC |
| Adage Capital Management, L.P. | 13G/A | 6.37%8.00M shares | −3.62 ppfrom 9.99% | Nov 13, 20252 filings | May 13, 2026 | SEC |